Johnson & Johnson experienced upward momentum driven by a combination of regulatory milestones in its MedTech division and strategic expansion across its biopharmaceutical pipeline. A primary catalyst behind the market focus was the FDA clearance of the MONARCH QUEST 3 bronchoscopy system, which highlighted the company’s deepening capabilities in robotic and technology-driven medical solutions. In parallel, investor enthusiasm was bolstered by JNJ securing an exclusive option agreement to acquire Sail Biomedicines, aiming to advance cutting-edge in vivo CAR-T cell therapies for immune-mediated diseases. These developments reinforced confidence in the company’s capacity to drive future revenue through targeted innovation and clinical…